Developing the Caf1 polymer technology into a commercial propositionEP/T005963/1
将 Caf1 聚合物技术开发为商业提案EP/T005963/1
基本信息
- 批准号:BB/T017198/1
- 负责人:
- 金额:$ 24.26万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2020
- 资助国家:英国
- 起止时间:2020 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Pharmaceuticals have developed via three manufacturing revolutions. The first arose in the 19th century from the ability to chemically synthesise drugs previously only obtainable from natural sources (aspirin, quinine). Next in the 1970's the biotechnology revolution enabled proteins such as insulin, clotting factors or antibodies to be developed into safe widespread treatments. Currently we are in the midst of the cell therapy revolution where the ability to grow human cells outside the body is being exploited to create cell based treatments.More generally, artificial cell culture is a widespread and rapidly expanding technology with applications in medicine, bioprocessing, crop science, drug development and clinical research. In recent years the idea of cell based therapies has moved from mere possibility to actual treatments for conditions such as leukaemia, stroke, blindness and arthritis. These require not only that cells can be grown outside the body but that they can be multiplied and modified before reintroduction into the patient. In many cases the body's immune system restricts cell therapies to autologous forms where the original cells are obtained from the patient, grown and or modified and then reintroduced. However several allogeneic treatments, where a commercial cell line is used to treat many patients, are also in development for conditions such as stroke or inherited blindness.Much work depends upon growing stem cells which are a "raw material" that can be transformed into a wide range of tissue types for medical applications. Growing sufficient numbers of stem cells to satisfy the needs of various treatments is still a significant challenge. Cells used in research laboratories are often selected for their ability to grow rapidly and indefinitely on plastic surfaces but cells for therapy need life like environments and grow in a highly regulated manner.Currently, cells are cultured on surfaces that largely fall into two groups; low cost, bulk materials, exemplified by plastic dishes, or high cost, low volume biological matrices which recreate the conditions found within the body and are increasingly important as more demanding or fragile cell types are used. This project seeks to use a recently developed and patented industrial process to overturn this product landscape by manufacturing engineered protein polymers with advanced cellular functions at low cost. By bridging the gap between traditional polymer science and protein biochemistry we can create a range of matrices to assist the growth of cells for many downstream applications. The 18 month project, supported by the Cell and Gene Therapy Catapult will start by developing one lead product for use in the rapidly expanding stem cell industry. This uses simple coating of plastic surfaces by our protein polymer and has already shown significant advantages over rival technologies in stem cell culture in our hands. Independent validation will enable us to embark on its commercial exploitation to reduce costs and increase efficiency of the whole cell therapy sector. We then intend to further demonstrate its wider applicability for work on muscle, nerve and cartilage by collaboration with leading research groups in the field and with industry. We will also test its usefulness in recreating even more realistic 3 dimensional environments for cell and tissue culture.Finally by exploiting a recent development by us to include large protein modules within the polymer we will create a matrix which can be decorated with any number of cell modifying molecules which are found in natural extracellular environment. This offers an unprecedented opportunity to create bespoke complex cell growth environments in the "test tube"Using both readily commercialisable products and the new intellectual property we intend to move decisively toward either spin out company or licensing agreement at the end of this project.
制药行业经历了三次制造革命。第一个起源于19世纪,源于化学合成药物的能力,以前只能从自然来源(阿司匹林、奎宁)获得。接下来,在20世纪70年代的S,生物技术革命使胰岛素、凝血因子或抗体等蛋白质得以开发成安全、广泛的治疗方法。目前,我们正处于细胞治疗革命中,人们正在利用体外培养人类细胞的能力来创造基于细胞的治疗。更广泛地说,人工细胞培养是一项广泛且迅速发展的技术,应用于医学、生物加工、作物科学、药物开发和临床研究。近年来,基于细胞的疗法的想法已经从纯粹的可能性转向对白血病、中风、失明和关节炎等疾病的实际治疗。这些要求不仅要求细胞可以在体外培养,而且需要在重新引入患者体内之前进行增殖和修改。在许多情况下,身体的免疫系统将细胞疗法限制在自体形式,即从患者那里获得原始细胞,进行培养和/或修改,然后重新引入。然而,几种使用商业细胞系治疗许多患者的同种异体疗法也在开发中,以治疗中风或遗传性失明等疾病。这项工作主要依赖于干细胞的培养,干细胞是一种可以转化为多种组织类型的医疗应用。培养足够数量的干细胞以满足各种治疗的需要仍然是一个巨大的挑战。研究实验室中使用的细胞通常是因为它们在塑料表面上快速和无限期生长的能力而被选择,但用于治疗的细胞需要类似环境的生命,并以高度调控的方式生长。目前,细胞在主要分为两类的表面上培养:低成本的大宗材料,如塑料培养皿;或高成本的低容量生物基质,其重建体内发现的条件,并随着要求更高或更脆弱的细胞类型的使用而变得越来越重要。该项目寻求使用最近开发并获得专利的工业工艺,通过以低成本制造具有先进细胞功能的工程蛋白聚合物来颠覆这一产品格局。通过弥合传统聚合物科学和蛋白质生物化学之间的差距,我们可以创建一系列基质,以帮助许多下游应用的细胞生长。在细胞和基因治疗弹射器的支持下,这项为期18个月的项目将从开发一种用于快速发展的干细胞行业的主导产品开始。它使用我们的蛋白质聚合物在塑料表面进行简单的涂层,并且在我们手中的干细胞培养方面已经显示出比竞争对手技术的显著优势。独立的验证将使我们能够开始其商业开发,以降低成本,提高整个细胞治疗部门的效率。然后,我们打算通过与该领域和行业的领先研究小组合作,进一步证明它在肌肉、神经和软骨工作中的更广泛适用性。我们还将测试它在为细胞和组织培养重建更逼真的三维环境中的有效性。最后,通过利用我们最近的一项发展,在聚合物中包括大型蛋白质模块,我们将创建一种基质,可以用在自然细胞外环境中发现的任意数量的细胞修饰分子来装饰。这提供了一个前所未有的机会,可以使用易于商业化的产品和新的知识产权在“试管”中创造定制的复杂细胞生长环境,我们打算在这个项目结束时果断地向剥离公司或许可协议迈进。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Unraveling the molecular determinants of the anti-phagocytic protein cloak of plague bacteria.
- DOI:10.1371/journal.ppat.1010447
- 发表时间:2022-03
- 期刊:
- 影响因子:6.7
- 作者:
- 通讯作者:
Exploiting Meltable Protein Hydrogels to Encapsulate and Culture Cells in 3D.
利用可熔蛋白质水凝胶封装和培养 3D 细胞。
- DOI:10.1002/mabi.202200134
- 发表时间:2022
- 期刊:
- 影响因子:4.6
- 作者:Dura G
- 通讯作者:Dura G
Spatial-Controlled Coating of Pro-Angiogenic Proteins on 3D Porous Hydrogels Guides Endothelial Cell Behavior.
- DOI:10.3390/ijms232314604
- 发表时间:2022-11-23
- 期刊:
- 影响因子:5.6
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy Lakey其他文献
Interfacial structure and protein incorporation in sparsely tethered phospholipid membranes
稀疏连接的磷脂膜中的界面结构和蛋白质结合
- DOI:
10.1016/j.jcis.2025.01.224 - 发表时间:
2025-05-15 - 期刊:
- 影响因子:9.700
- 作者:
Martynas Gavutis;Nicolò Paracini;Jeremy Lakey;Ramūnas Valiokas;Luke A. Clifton - 通讯作者:
Luke A. Clifton
Jeremy Lakey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy Lakey', 18)}}的其他基金
Manufacture of complex protein polymers for industry and medicine
工业和医药用复杂蛋白质聚合物的制造
- 批准号:
BB/M018318/1 - 财政年份:2015
- 资助金额:
$ 24.26万 - 项目类别:
Research Grant
Surveillance of toxic threats by electronic supervision of synthetic neurons in 3D
通过 3D 合成神经元的电子监控来监测有毒威胁
- 批准号:
BB/J020176/1 - 财政年份:2012
- 资助金额:
$ 24.26万 - 项目类别:
Research Grant
Rapid diagnostic biosensors for the detection of respiratory viruses (VIRASENS)
用于检测呼吸道病毒的快速诊断生物传感器 (VIRASENS)
- 批准号:
TS/G001561/1 - 财政年份:2009
- 资助金额:
$ 24.26万 - 项目类别:
Research Grant
Delta3D; Bench top assays for the rapid detection of protein 3D structural changes
Delta3D;
- 批准号:
BB/F005768/1 - 财政年份:2008
- 资助金额:
$ 24.26万 - 项目类别:
Research Grant
相似国自然基金
组蛋白H3.1-H4分子伴侣CAF1复合体参与拟南芥细胞全能性调控的分子机制
- 批准号:32370621
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CAF1在Tristetraprolin调控ICAM-1和IL-8表达中的作用及其对急性肺损伤的影响
- 批准号:81300052
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
脱腺苷酸化酶CCR4和CAF1同工酶的不同性质、相互作用和功能研究
- 批准号:31170757
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Developing novel animal cell lines and processes incoperating engineered caf1 to scale cultured meat protein manufacturing
开发新型动物细胞系和工艺,与工程化 caf1 相结合,以扩大培养肉蛋白生产规模
- 批准号:
10076199 - 财政年份:2023
- 资助金额:
$ 24.26万 - 项目类别:
Collaborative R&D
Coordination of DNA and chromatin replication by CAF1 phosphorylation.
通过 CAF1 磷酸化协调 DNA 和染色质复制。
- 批准号:
373864-2009 - 财政年份:2010
- 资助金额:
$ 24.26万 - 项目类别:
Postdoctoral Fellowships
Coordination of DNA and chromatin replication by CAF1 phosphorylation.
通过 CAF1 磷酸化协调 DNA 和染色质复制。
- 批准号:
373864-2009 - 财政年份:2009
- 资助金额:
$ 24.26万 - 项目类别:
Postdoctoral Fellowships